​

MapLight Therapeutics (MPLT) Stock Forecast, Price Target & Predictions

OverviewOwnershipChart

MPLT Stock Forecast

MapLight Therapeutics (MPLT) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $29.20, with a high of $46.00 and a low of $13.00. This represents a 369.45% increase from the last price of $6.22.

$5 $14 $23 $32 $41 $50 High: $46 Avg: $29.2 Low: $13 Last Closed Price: $6.22

MPLT Stock Rating

MapLight Therapeutics stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (71.43%), 2 Hold (28.57%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 2 5 Strong Sell Sell Hold Buy Strong Buy

MPLT Price Target Upside V Benchmarks

TypeNameUpside
StockMapLight Therapeutics369.45%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-423
Avg Price Target-$27.00$34.87
Last Closing Price$6.22$6.22$6.22
Upside/Downside-334.08%460.61%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 261113--15
Oct, 261112--14
Sep, 261112--14
Aug, 261121--14
Jul, 26210---12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 31, 2026Ami FadiaNeedham$43.00$12.60241.27%591.32%
Aug 14, 2026Sumant KulkarniCanaccord Genuity$21.00$11.6380.57%237.62%
Aug 14, 2026Raymond James$31.00$11.59167.47%398.39%
Aug 10, 2026UBS$13.00$12.176.82%109.00%
Jul 28, 2026Adam VogelCraig-Hallum$25.00$10.21144.86%301.93%
Jul 28, 2026Sumant KulkamiCanaccord Genuity$24.00$9.91142.18%285.85%
Jul 28, 2026Morgan Stanley$21.00$9.91111.91%237.62%
Jul 28, 2026Raghuram SelvarajuH.C. Wainwright$26.00$9.91162.36%318.01%
Jul 27, 2026Rudy LiWolfe Research$30.00$9.91202.72%382.32%
Jul 24, 2026Sumant KulkarniCanaccord Genuity$43.00$35.2322.06%591.32%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 05, 2026GuggenheimNeutralinitialise
Aug 31, 2026NeedhamBuyBuyhold
Aug 10, 2026UBSBuyNeutraldowngrade
Jul 28, 2026Craig-HallumBuyBuyhold
Jul 28, 2026H.C. WainwrightBuyBuyhold
Jul 27, 2026Wolfe ResearchOutperformOutperformhold
Jul 27, 2026JefferiesBuyBuyhold
Jul 21, 2026UBSBuyBuyhold
Jul 20, 2026BMO CapitalOutperforminitialise
Jul 10, 2026NeedhamBuyBuyhold

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 Dec 25 Dec 26
Dec 25Dec 26
Reported--
Avg Forecast$-5.15$-3.65
High Forecast$-3.50$-2.78
Low Forecast$-6.47$-4.40
Surprise %--

Revenue Forecast

Dec 25 Dec 26
Dec 25Dec 26
Reported--
Avg Forecast--
High Forecast--
Low Forecast--
Surprise %--

Net Income Forecast

$-300M $-260M $-220M $-180M $-140M $-100M Dec 25 Dec 26
Dec 25Dec 26
Reported--
Avg Forecast$-213.36M$-151.22M
High Forecast$-145.00M$-115.17M
Low Forecast$-268.05M$-182.29M
Surprise %--

MPLT Forecast FAQ

Is MapLight Therapeutics stock a buy?

MapLight Therapeutics stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that MapLight Therapeutics is a favorable investment for most analysts.

What is MapLight Therapeutics's price target?

MapLight Therapeutics's price target, set by 7 Wall Street analysts, averages $29.2 over the next 12 months. The price target range spans from $13 at the low end to $46 at the high end, suggesting a potential 369.45% change from the previous closing price of $6.22.

How does MapLight Therapeutics stock forecast compare to its benchmarks?

MapLight Therapeutics's stock forecast shows a 369.45% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for MapLight Therapeutics over the past three months?

  • November 2026: 6.67% Strong Buy, 73.33% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • October 2026: 7.14% Strong Buy, 78.57% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 7.14% Strong Buy, 78.57% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.

What is MapLight Therapeutics’s EPS forecast?

MapLight Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-5.15, marking a 0% decrease from the reported - in 2024. Estimates for the following years are.

What is MapLight Therapeutics’s revenue forecast?

MapLight Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported - in 2024. The forecast for.

What is MapLight Therapeutics’s net income forecast?

MapLight Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-213M, representing a 0% decrease from the reported - in 2024. Projections indicate .